1. < Home

abdominal pain

Editorial: Alpha2-Delta Ligands in Irritable Bowel Syndrome

Shin A. Editorial: Alpha2-Delta Ligands in Irritable Bowel Syndrome. Aliment Pharmacol Ther. 2025 Jan 30. doi: 10.1111/apt.18528. Epub ahead of print. PMID: 39888072.

By sjmartinez • February 1, 2025
Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma

Cai J, Varda M, Sin D, Overby H, Yeh JJ. Unusual painful pelvic masses: Extramedullary hematopoiesis with extramedullary multiple myeloma. Clin Case Rep. 2024 May[...]

By sjmartinez • May 6, 2024
An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment of Irritable Bowel Syndrome with Constipation

Singh P, Sayuk GS, Rosenbaum DP, Edelstein S, Kozuka K, Chang L. An Overview of the Effects of Tenapanor on Visceral Hypersensitivity in the Treatment[...]

By sjmartinez • April 15, 2024
Female patients delay seeking medical care with alcohol-associated acute pancreatitis

Jeon CY, Adeniran E, Stewart C, Papachristou GI, Pisegna JR, Kuc AA, Buxbaum JL, Pandol SJ, Yadav D. Female patients delay seeking medical care with[...]

By sjmartinez • August 13, 2023
Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis Using New End Points

Lacy BE, Chang L, Rao SSC, Heimanson Z, Sayuk GS. Rifaximin Treatment for Individual and Multiple Symptoms of Irritable Bowel Syndrome With Diarrhea: An Analysis[...]

By sjmartinez • March 16, 2023
Efficacy and safety of olorinab, a full agonist of the cannabinoid receptor 2, for the treatment of abdominal pain in patients with irritable bowel syndrome: Results from a phase 2b randomized placebo-controlled trial (CAPTIVATE)

Chang L, Cash BD, Lembo A, Kunkel DC, English BA, Lindstrom B, Gu G, Skare S, Gilder K, Turner S, Cataldi F, Lipkis D, Jan[...]

By sjmartinez • February 7, 2023